Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147

NCT01215136 is registered in ClinicalTrials.gov with Matthew Galsky as lead sponsor.

NCT NCT01215136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01215136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Lead sponsor
Matthew Galsky
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2010
Completion date
April 24, 2018
Enrollment
36 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

bladder carcinoma, transitional cell carcinoma, urothelial carcinoma